67 results  1 of 4 

1 Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
Yong-Pyo Lee, Min-Sang Lee, HongSik Kim, Ji-Yeon Kim, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat.2022;54(4):1130-1137.   Published online 2022 January 17     DOI: http://dx.doi.org/10.4143/crt.2021.1103
      
2 A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer
Hye Ryeon Kim, Su Jin Lee, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Han-Sin Jeong, Man Ki Chung, Myung-Ju Ahn
Cancer Res Treat.2022;54(3):719-727.   Published online 2021 November 1     DOI: http://dx.doi.org/10.4143/crt.2021.1019
      
3 Docetaxel-loaded PLGA nanoparticles to increase pharmacological sensitivity in MDA-MB-231 and MCF-7 breast cancer cells
Phuong Tran, Thu Nhan Nguyen, Yeseul Lee, Phan Nhan Tran, Jeong-Sook Park
Korean J Physiol Pharmacol.2021;25(5):479-488.   Published online 2021 September 1     DOI: http://dx.doi.org/10.4196/kjpp.2021.25.5.479
      
4 Potentiation of the Anticancer Effects by Combining Docetaxel with Ku-0063794 against Triple-Negative Breast Cancer Cells
Ye-Won Jeon, Ok-Hee Kim, Jin Sun Shin, Ha Eun Hong, Cho Hee Kim, Say-June Kim
Cancer Res Treat.2022;54(1):157-173.   Published online 2021 April 5     DOI: http://dx.doi.org/10.4143/crt.2020.1063
      
5 Synergistic anticancer activity of resveratrol in combination with docetaxel in prostate carcinoma cells
Sang-Han Lee, Yoon-Jin Lee
Nutr Res Pract.2021;15(1):12-25.   Published online 2020 September 3     DOI: http://dx.doi.org/10.4162/nrp.2021.15.1.12
      
6 Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
Kyungchan Min, Jae-Wook Chung, Yun-Sok Ha, Jun Nyung Lee, Bum Soo Kim, Hyun Tae Kim, Tae-Hwan Kim, Eun Sang Yoo, Tae Gyun Kwon, Sung Kwang Chung, Masatoshi Tanaka, Shin Egawa, Takahiro Kimura, Seock Hwan Choi
World J Mens Health.2020;38(2):226-235.   Published online 2019 June 4     DOI: http://dx.doi.org/10.5534/wjmh.190029
      
7 Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
Whi-An Kwon, Jae Young Joung, Jung Eun Lee, Se Young Choi, Sung Han Kim, Ho Kyung Seo, Kang Hyun Lee, Choung-Soo Kim
Investig Clin Urol.2019;60(3):195-201.   Published online 2019 April 18     DOI: http://dx.doi.org/10.4111/icu.2019.60.3.195
      
8 The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma
Jong Hyun Choi, Juwhan Choi, Sang Mi Chung, Jee Youn Oh, Young Seok Lee, Kyung Hoon Min, Gyu Young Hur, Jae Jeong Shim, Kyung Ho Kang, Hyun Kyung Lee, Sung Yong Lee
Tuberc Respir Dis.2019;82(3):211-216.   Published online 2018 December 20     DOI: http://dx.doi.org/10.4046/trd.2018.0019
      
9 ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line
Eunjoo Hwang, Seong-Hye Hwang, Jongjin Kim, Jin Hyun Park, Sohee Oh, Young A Kim, Ki-Tae Hwang
Ann Surg Treat Res.2018;95(5):240-248.   Published online 2018 October 25     DOI: http://dx.doi.org/10.4174/astr.2018.95.5.240
      
10 Prediction of Acquired Taxane Resistance Using a Personalized Pathway-Based Machine Learning Method
Young Rae Kim, Dongha Kim, Sung Young Kim
Cancer Res Treat.2019;51(2):672-684.   Published online 2018 August 10     DOI: http://dx.doi.org/10.4143/crt.2018.137
      
11 Combined Effects of Baicalein and Docetaxel on Apoptosis in 8505c Anaplastic Thyroid Cancer Cells via Downregulation of the ERK and Akt/mTOR Pathways
Chan Ho Park, Se Eun Han, Il Seong Nam-Goong, Young Il Kim, Eun Sook Kim
Endocrinol Metab.2018;33(1):121-132.   Published online 2018 March 21     DOI: http://dx.doi.org/10.3803/EnM.2018.33.1.121
      
12 S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
Choong-kun Lee, Minkyu Jung, Hyo Song Kim, Inkyung Jung, Dong Bok Shin, Seok Yun Kang, Dae Young Zang, Ki Hyang Kim, Moon Hee Lee, Bong-Seog Kim, Kyung Hee Lee, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung, Sun Young Rha
Cancer Res Treat.2019;51(1):1-11.   Published online 2018 February 5     DOI: http://dx.doi.org/10.4143/crt.2018.028
      
13 A Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel and Gemcitabine in Locally Advanced Breast Cancer
Ye Won Jeon, Tae Hyun Kim, Hyun Jo Youn, Sehwan Han, Yongsik Jung, Geumhee Gwak, Young Sam Park, Jeong Soo Kim, Young Jin Suh
J Breast Cancer.2017;20(4):340-346.   Published online 2017 December 19     DOI: http://dx.doi.org/10.4048/jbc.2017.20.4.340
      
14 Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study
Yunjung Choi, Mi Sun Yun, Sang Hee Lim, Jeeyun Lee, Jin-Hee Ahn, Yu Jung Kim, Kyong Hwa Park, Young Suk Park, Ho Yeong Lim, Hyonggin An, Dong-Churl Suh, Yeul Hong Kim
Cancer Res Treat.2018;50(1):175-182.   Published online 2017 March 30     DOI: http://dx.doi.org/10.4143/crt.2016.535
      
15 Curative Resection of Inoperable, Locally Advanced Gastric Cancer after Neoadjuvant Chemotherapy with Taxotere and Cisplatin
Han Hong Lee, Hoon Hur, Byung Joo Chae, Wook Kim, Hae Myung Jeon
J Korean Gastric Cancer Assoc.2005;5(1):57-64.   Published online 2017 March 13     DOI: http://dx.doi.org/10.5230/jkgca.2005.5.1.57
   
16 A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
Keun-Wook Lee, Bum Jun Kim, Mi-Jung Kim, Hye Sook Han, Jin Won Kim, Young Iee Park, Sook Ryun Park
Cancer Res Treat.2017;49(3):706-716.   Published online 2016 October 18     DOI: http://dx.doi.org/10.4143/crt.2016.216
      
17 Knockdown of the M2 Isoform of Pyruvate Kinase (PKM2) with shRNA Enhances the Effect of Docetaxel in Human NSCLC Cell Lines In Vitro
Sujuan Yuan, Tiankui Qiao, Xibing Zhuang, Wei Chen, Na Xing, Qi Zhang
Yonsei Med J.2016;57(6):1312-1323.   Published online 2016 August 30     DOI: http://dx.doi.org/10.3349/ymj.2016.57.6.1312
      
18 Parameters of Stromal Activation and Epithelial to Mesenchymal Transition as Predictive Biomarkers for Induction Chemotherapy in Patients With Locally Advanced Oral Cavity and Oropharyngeal Squamous Cell Cancer
Jana Geweiler, Johanna Inhestern, Alexander Berndt, Orlando Guntinas-Lichius
Clin Exp Otorhinolaryngol.2016;9(4):374-381.   Published online 2016 July 2     DOI: http://dx.doi.org/10.21053/ceo.2015.01683
      
19 Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
Ho Seong Jang, Kyo Chul Koo, Kang Su Cho, Byung Ha Chung
Yonsei Med J.2016;57(5):1070-1078.   Published online 2016 June 30     DOI: http://dx.doi.org/10.3349/ymj.2016.57.5.1070
      
20 Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy
Chang Gon Kim, Joohyuk Sohn, Hongjae Chon, Joo Hoon Kim, Su Jin Heo, Hyunsoo Cho, In Jung Kim, Seung Il Kim, Seho Park, Hyung Seok Park, Gun Min Kim
J Breast Cancer.2016;19(1):76-82.   Published online 2016 March 25     DOI: http://dx.doi.org/10.4048/jbc.2016.19.1.76
      

 1 of 4